Search

Author/Creator Michaelson, M. Dror

1. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. (6th June 2019)

Authors:
Michaelson, M. Dror; Gupta, Shilpa; Agarwal, Neeraj; Szmulewitz, Russell; Powles, Thomas; Pili, Roberto; Bruce, Justine Yang; Vaishampayan, Ulka; Larkin, James; Rosbrook, Brad; Wang, Erjian; Murphy, Danielle; Wang, Panpan; Lechuga, Maria Josè; Valota, Olga; Shepard, Dale R.
Journal:
Oncologist
Issue:
Volume 24:Number 9(2019)
Page Start:
1151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (6th September 2018)

Authors:
Choueiri, Toni K.; Michaelson, M. Dror; Posadas, Edwin M.; Sonpavde, Guru P.; McDermott, David F.; Nixon, Andrew B.; Liu, Yingmiao; Yuan, Zhenhua; Seon, Ben K.; Walsh, Meghara; Jivani, Manoj A.; Adams, Bonne J.; Theuer, Charles P.
Journal:
Oncologist
Issue:
Volume 24:Number 2(2019)
Page Start:
202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. (16th February 2022)

Authors:
McGregor, Bradley A.; Xie, Wanling; Adib, Elio; Stadler, Walter M.; Zakharia, Yousef; Alva, Aijai; Michaelson, M. Dror; Gupta, Shilpa; Lam, Elaine T.; Farah, Subrina; Nassar, Amin H.; Wei, Xiao X.; Kilbridge, Kerry L.; Harshman, Lauren; Signoretti, Sabina; Sholl, Lynette; Kwiatkowski, David J.; M...
Journal:
JCO precision oncology
Issue:
Volume 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (May 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 94(2018)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. (9th August 2019)

Authors:
George, Daniel J.; Hessel, Colin; Halabi, Susan; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J.; Choueiri, Toni K.
Journal:
Oncologist
Issue:
Volume 24:Number 11(2019)
Page Start:
1497
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma. Issue 12 (13th March 2014)

Authors:
Cella, David; Davis, Mellar P.; Négrier, Sylvie; Figlin, Robert A.; Michaelson, M. Dror; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Sandin, Rickard; Korytowsky, Beata; Charbonneau, Claudie; Matczak, Ewa; Motzer, Robert J.
Journal:
Cancer
Issue:
Volume 120:Issue 12(2014)
Page Start:
1871
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma. Issue 12 (13th March 2014)

Authors:
Cella, David; Davis, Mellar P.; Négrier, Sylvie; Figlin, Robert A.; Michaelson, M. Dror; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Sandin, Rickard; Korytowsky, Beata; Charbonneau, Claudie; Matczak, Ewa; Motzer, Robert J.
Journal:
Cancer
Issue:
Volume 120:Issue 12(2014)
Page Start:
1871
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125]. (November 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 103(2018)
Page Start:
287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗